The estimated Net Worth of Stephen S. Dominy is at least $2.87 Milhão dollars as of 12 November 2021. Mr. Dominy owns over 763 units of Cortexyme Inc stock worth over $2,373,318 and over the last 5 years he sold CRTX stock worth over $0. In addition, he makes $497,344 as Co-Founder, Chief Scientific Officer, e Director at Cortexyme Inc.
Sign up
Mr. Dominy CRTX stock SEC Form 4 insiders trading
Stephen has made over 1 trades of the Cortexyme Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 763 units of CRTX stock worth $10,987 on 12 November 2021.
The largest trade he's ever made was buying 763 units of Cortexyme Inc stock on 12 November 2021 worth over $10,987. On average, Stephen trades about 191 units every 0 days since 2020. As of 12 November 2021 he still owns at least 1,217,086 units of Cortexyme Inc stock.
You can see the complete history of Mr. Dominy stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Stephen Dominy biography
Stephen S. Dominy M.D. serves as Co-Founder, Chief Scientific Officer, Director of the Company. Dr. Dominy has served as a member of our board of directors since December 2015 and as our Chief Scientific Officer since April 2016. Prior to co-founding Cortexyme, Dr. Dominy served as a Division Director at San Francisco General Hospital and as Associate Professor of Psychiatry at the University of California, San Francisco School of Medicine from 2006 to 2016. Dr. Dominy holds a B.S. in Pharmacy from The Ohio State University College of Pharmacy and an M.D. from the Wright State University Boonshoft School of Medicine. Dominy is qualified to serve as a director because of his educational background, as well as his extensive research and technical experience that provides an important perspective on operations and development.
What is the salary of Stephen Dominy?
As the Co-Founder, Chief Scientific Officer, e Director of Cortexyme Inc, the total compensation of Stephen Dominy at Cortexyme Inc is $497,344. There are 9 executives at Cortexyme Inc getting paid more, with Michael Detke having the highest compensation of $1,100,170.
How old is Stephen Dominy?
Stephen Dominy is 64, he's been the Co-Founder, Chief Scientific Officer, e Director of Cortexyme Inc since 2016. There are 2 older and 16 younger executives at Cortexyme Inc. The oldest executive at Cortexyme Inc is Una Ryan, 78, who is the Lead Independent Director.
What's Stephen Dominy's mailing address?
Stephen's mailing address filed with the SEC is C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Cortexyme Inc
Over the last 21 years, insiders at Cortexyme Inc have traded over $59,595,534 worth of Cortexyme Inc stock and bought 19,273,711 units worth $164,053,955 . The most active insiders traders include & Johnson Johnson & Johnson..., Farmaceutici Sp A Chiesi, eAnsbert Gadicke. On average, Cortexyme Inc executives and independent directors trade stock every 59 days with the average trade being worth of $475,426. The most recent stock trade was executed by Caryn Gordon Mc Dowell on 6 June 2022, trading 10,800 units of CRTX stock currently worth $30,888.
What does Cortexyme Inc do?
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.
What does Cortexyme Inc's logo look like?
Complete history of Mr. Dominy stock trades at Cortexyme Inc
Cortexyme Inc executives and stock owners
Cortexyme Inc executives and other stock owners filed with the SEC include:
-
Michael Detke,
Chief Medical Officer -
Margaret Mcloughlin,
Independent Director -
Casey C. Lynch,
Co-Founder, Chairman, Pres & CEO -
Christopher Senner,
Independent Director -
Dr. Michael J. Detke M.D., Ph.D.,
Chief Medical Officer -
Dr. Leslie J. Holsinger Ph.D.,
Exec. VP of R&D -
Casey Lynch,
Chairman of the Board, President, Chief Executive Officer, Co-Founder -
Christopher P. Lowe M.B.A.,
COO, CFO & Treasurer -
Caryn Gordon McDowell,
Chief Legal & Admin. Officer and Corp. Sec. -
Stephen Dominy,
Co-Founder, Chief Scientific Officer, Director -
Una Ryan,
Lead Independent Director -
Kevin Young,
Independent Director -
Christopher Lowe,
Chief Financial Officer, Treasurer -
David Lamond,
Independent Director -
Dr. Stephen S. Dominy,
Co-Founder, Chief Scientific Officer & Director -
Caryn McDowell,
Chief Legal and Administrative Officer, Corporate Secretary -
Leslie Holsinger,
Executive Vice President - Preclinical Development -
Dr. Karen L. Smith L.L.M, L.L.M., M.B.A., M.D., PH.D.,
Chief Medical Officer -
Brendan Hannah M.B.A.,
Chief Bus. Officer -
Dr. Dirk Thye M.D.,
CEO & Director -
Mary Ellen Sillivos,
VP of HR -
Stacy Roughan,
VP of Corp. Communications & IR -
Ted Monohon,
VP of Fin. & Chief Accounting Officer -
Ansbert Gadicke,
-
James B Tananbaum,
Director -
Christopher T Phd Walsh,
Director -
Richard W Dugan,
Director -
M Cory Zwerling,
Director -
Luke Evnin,
-
Michael Steinmetz,
-
Kurt Wheeler,
-
Nicholas Galakatos,
Director -
Bioventures Ii Qp Lpmpm Bio...,
-
Dana Charles Hilt,
SVP of Clinical Develop. & CMO -
Philip S Low,
Director -
Marwan Sabbagh,
Director -
Brendan Hannah,
Chief Business Officer -
Dirk Thye,
Chief Executive Officer -
Karen L. Smith,
Chief Medical Officer -
Laura Shawver,
Director -
Michael Thomas Heffernan,
Director -
Andreas Maetzel,
VP, Clinical and Regulatory -
Robert Stephan,
Director -
Alan Roberts,
VP, Scientific Affairs -
Craig A Collard,
President and CEO -
James A Harper,
Director -
Ira Duarte,
Principal Accounting Officer -
Alastair Stuart Mcewan,
Director -
Farmaceutici Sp A Chiesi,
10% owner -
Christopher George Codeanne,
Director -
Joshua B Franklin,
VP, Sales and Marketing -
Marco Vecchia,
Director -
Kenneth Mc Bean,
President -
Anton Giorgio Failla,
Director -
Michael David Enright,
Director -
Ventures, Inc.Takeda Pharma...,
-
Paul D Rubin,
President and CEO -
Inc Pfizer Ventures (Us) Ll...,
-
Pierre Lamond Christine Lamond,
-
Walter Newman,
Chief Scientific Officer/VP RD -
Howland Shaw Warren,
Director -
Frederick Finnegan,
VP of Sales and Marketing -
Robert H Zeiger,
Director -
Technology Ventures Vii Lp ...,
-
Christopher Mirabelli,
Director -
Ventures Vi Lphealthcare Pa...,
-
Jean George,
Director -
Ventures, Inc. Med Immune,
10% owner -
Bioventures Iii Qp Lpmpm Bi...,
-
Jean Advanced Technology Ve...,
-
Frank E Thomas,
CFO, VP Finance and Treasurer -
& Johnson Johnson & Johnson...,
-
Alessandro Chiesi,
Director -
Vincent T. Morgus,
EVP, Finance and CFO -
Brian Dickson,
Chief Medical Officer -
Steven Michael Lutz,
Executive Vice President -
David Price,
Chief Financial Officer -
Bio Pharma Holdings, Ltd. C...,
10% owner -
Scott B Townsend,
VP OF LEGAL AFFAIRS AND SEC. -
Jeffrey E Young,
VP FINANCE, CAO AND TREASURER -
Trevor Phillips,
COO, VP of Operations and Sec. -
George Arthur Esgro,
Vice President Sales -
Chenyqua Michele Baldwin,
Vice President Finance -
Thomas Patrick Kelly,
CFO & SVP Finance & Corp. Dev, -
Capital Group, Llc Boeding ...,
-
Kristen Gafric,
SVP, Legal & Administration -
Inc Pfizer Strategic Invest...,
-
Ted Monohon,
Chief Accounting Officer & VP -
June Bray,
Director